HIV Infections Clinical Trial
Official title:
Survey of Intestinal Protozoal Infections and Sexual Transmitted Diseases Among Targeted Cohorts
In this two-year study, we will target two high risk groups, including MSM of HIV-infected and those of non-HIV-infected. We will avail the serodiagnosis to detect the potential amebic carriers in both groups; and use microscopy to detect protozoas other than amebiasis. Meanwhile we will also survey the patients' status of sexual transmitted diseases (STD). For the amebic carriers, we will apply specific antigen and molecular biologic method to follow up the duration of the persistence of fecal amebas. We try to clarify the dynamic change of amebic carriage.
HIV-infected persons who are men having sex with men (MSM) are prone to acquire invasive
amebiasis. It would cast great threat for public health if the pathogens are spread by way
of human to human transmission and food contamination.
From 2000 to 2004, we assessed the seroprevalence of Entamoeba histolytica infection using
indirect hemagglutination antibody (IHA) assay among 667 HIV-infected persons (group 1),
1311 asymptomatic HIV-uninfected persons seeking anonymous HIV testing (group 2), 616
HIV-uninfected controls with gastrointestinal symptoms (diarrhea and/or liver abscess)
seeking medical care (group 3), and 2500 healthy controls undergoing health check-up (group
4). An IHA titer greater than 128 was detected in 7.1% of group 1, 2.5% of group 2, 1.8% of
group 3, and 0.1% of group 4 (p<0.0001). The highest seroprevalence (11.2%) was noted among
HIV-infected persons who were MSM aged 30 to 39 years. Compared with persons with
gastrointestinal symptoms, the adjusted odds ratio for having high IHA titers among
HIV-infected persons was 3.206 (95% confidence interval, 1.433, 7.176) (p=0.005). These
findings demonstrate that HIV-infected persons, especially MSM aged 30 to 39 years, are at
significantly higher risk of E. histolytica infection.
In this two-year study, we will target two high risk groups, including MSM of HIV-infected
and those of non-HIV-infected. We will avail the serodiagnosis to detect the potential
amebic carriers in both groups; and use microscopy to detect protozoas other than amebiasis.
Meanwhile we will also survey the patients' status of sexual transmitted diseases (STD). For
the amebic carriers, we will apply specific antigen and molecular biologic method to follow
up the duration of the persistence of fecal amebas. We try to clarify the dynamic change of
amebic carriage.
We anticipate this study could outline the epidemiology and risk factors of protozoal
infections and STD in MSM cohorts. We also hope to reduce the the infection rate (protozoa
and HIV) and disease rate (STD) through the repetitively effective health education and
consultation during the conduct of this study.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |